TAR-0520 Gel in EGFR Inhibitor-induced Folliculitis

Tarian Pharma

Status and phase

Enrolling

Phase 2

Conditions

EGFR Inhibitor-associated Rash

Treatments

Drug: Placebo gel (no Brimonidine tartrate)

Drug: Brimonidine tartrate Gel

Study type

Interventional

Funder types

Industry

Identifiers

NCT06818058

TARIAN 007

2024-516339-28-00 (EU Trial (CTIS) Number)

Details and patient eligibility

About

A Phase II, multicentric, randomized, double-blind, placebo-controlled, parallel- group trial to confirm the good safaty profile and to explore the preventive effect of topically applied TAR-0520 gel on folliculitis developed in metastatic colorectal cancer (mCRC) patients treated with monoclonal anti-EGFR antibodies.

Full description

Cetuximab and panitumumab hae become the standard treatment for patients with metastatic colorectal cancer without RAS gene mutation. Hoever, these EGFR inhbitors induce a broad spectrum of cutaneous toxicities (skin side effects) in 75-90% of patients, including the folliculitis involving the face,upper torso and scalp. The folliculitis appears within 1-2 weeks of anti-EGFR therapy and peaks around 3-5 weeks of treatment. There is no approved treatment to prevent or treat EGFR-induced folliculitis. Tarian Pharma has developed a new topical treatment of EGFRi-induced folliculitis.This study aims to confirm the good safety of TAR-0520 gel in colorectal cancer patients treated with cetuximab or panitmumab and eplore , in the same patients , the effect of TAR-0520 gel on the extent and severity of EGFRi-induced folliculitis.

Patients aged 18 years and over with metastatic colorectal carcinoma planned to be treated with cetuximab or panitumumab injections will be included in the study.

Participants will be randomly allocated to receive either the topical active TAR-0520 gel or its vehicle.The study will include a 7days treatment period with once daily applications of the test product followed by a treatment free period until the start of the next chemotherapy cycle usually 7 days later.The study will cover 4 complete chemotherapy cycles, thus lasting at least 56 days.

Enrollment

60 estimated patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

male or female, who is at least 18 years of age or older at the screening visit
patients with clinical diagnosis of metastatic colorectal carcinoma planned to be treated with cetuximab or panitumumab injections as part of the chemotherapy protocol
patients who can understand and sign the Informed Consent Form, can communicate with investigator,can understand and comply with requierements of the protocol, and can apply the study gel by himself/herself or have giver who can apply the product
patients with predicted life expectency of > 3 months
patients willing and able to comply with all of the time commitements and procedural requirements of the clinical trial protocol

Exclusion criteria

patients with medical history of EGFR treatment in the past 2 years
patients with any underlying physical ,psychological or medical condition that, in the opinion of the invstigator, would make it unlikely that the patient will comply with the protocol or complete the study protocol
patients with any uncotrolled or serious disease, or any medical or surgical condition,that may put the subject at significant risk (according to the investigator's judgement) if he/she participates in the clinical trial
patients with history of other skin disorders (eg.atopic dermatitis,psoriasis,recurrent skin infections), or a history of illness that, in the opinion of the investigator, would confound the results of the study
patients with significant skin disease other than EGFRi-induced folliculits within the same body areas planned for study drug application
patients with a beard that would interfere with administration of the study drug and assessement of study endpoints
patients with active infection within the treatment area ot in other body areas that requieres initiation of systemic antibiotics
patients with known or suspected allergies or sensitivities to any components of the study drugs
female patients who are pregnant or lactating